Show simple item record

dc.contributor.authorAnnibaldi, A
dc.contributor.authorMeier, P
dc.date.accessioned2017-12-22T10:09:58Z
dc.date.issued2018-01-01
dc.identifier.citationTrends in molecular medicine, 2018, 24 (1), pp. 49 - 65
dc.identifier.issn1471-4914
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/986
dc.identifier.eissn1471-499X
dc.identifier.doi10.1016/j.molmed.2017.11.002
dc.description.abstractTumor necrosis factor (TNF) is a proinflammatory cytokine that coordinates tissue homeostasis by regulating cytokine production, cell survival, and cell death. However, how life and death decisions are made in response to TNF is poorly understood. Many inflammatory pathologies are now recognized to be driven by aberrant TNF-induced cell death, which, in most circumstances, depends on the kinase Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Recent advances have identified ubiquitin (Ub)-mediated phosphorylation of RIPK1 as belonging to crucial checkpoints for cell fate in inflammation and infection. A better understanding of these checkpoints might lead to new approaches for the treatment of chronic inflammatory diseases fueled by aberrant RIPK1-induced cell death, and/or reveal novel strategies for anticancer immunotherapies, harnessing the ability of RIPK1 to trigger immunogenic cell death.
dc.formatPrint-Electronic
dc.format.extent49 - 65
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectInflammation
dc.subjectTumor Necrosis Factor-alpha
dc.subjectNF-kappa B
dc.subjectUbiquitin
dc.subjectCell Death
dc.subjectReceptor-Interacting Protein Serine-Threonine Kinases
dc.titleCheckpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-11-13
rioxxterms.versionofrecord10.1016/j.molmed.2017.11.002
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfTrends in molecular medicine
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity
pubs.publication-statusPublished
pubs.volume24
pubs.embargo.termsNo embargo
icr.researchteamCell Death and Immunity
dc.contributor.icrauthorMeier, Pascal


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record